Biotech China 2014

New melanoma drug may shrink brain tumours

An experimental melanoma drug from GlaxoSmithKline (GSK.L) managed to shrink secondary tumours in the brains of nine patients with advanced disease, according to results of a small clinical trial on Sunday.

The development is encouraging because secondary tumours, or metastases, in the brain are a major problem in the deadly form of skin cancer.


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.